Description
Rasagiline is an inhibitor of monoamine oxidase B (MAO-B) that is used to treat Parkinson’s disease. Rasagiline may also exhibit effects on MAO-A, as actions on that enzyme are likely responsible for the ability of rasagiline to increase levels of Bcl-2, glial cell line-derived neurotrophic factor (GDNF), and brain-derived neurotrophic factor (BDNF). Rasagiline also displays neuroprotective activity, inhibiting mitochondrial membrane permeability, preventing caspase- and mitochondria-mediated apoptosis.